MONTREAL, Feb. 10, 2026 /CNW/ - fdp Private Wealth Management today announced the immediate acquisition of a majority interest in MultiD, further strengthening a long–standing relationship between two ...

Newly diagnosed prostate cancer patients have multiple standard-of-care treatment options available, but many are not fully informed of their choices. A study led by researchers at The University of ...

Concomitant medication (CM) use in phase I and II cancer clinical trials (CCT): Effects on trial eligibility and potential interactions with study medications. Background: MultiD decision making is ...

The impact of comprehensive genomic profiling in the management of patients with metastatic solid tumors in a developing country.

Simpler Prostate Cancer Grading System Proposed Receiving prostate cancer care at multidisciplinary clinics facilitates adherence to evidence-based national guidelines and potentially ameliorates bias ...